Andrea Angelini1, Andreas F Mavrogenis1, Giulia Trovarelli1, Stefano Ferrari2, Piero Picci3, Pietro Ruggieri4. 1. Department of Orthopedics, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy. 2. Department of Chemotherapy, Istituto Ortopedico Rizzoli, Bologna, Italy. 3. Department of Oncology, Istituto Ortopedico Rizzoli, Bologna, Italy. 4. Department of Orthopedics and Orthopedic Oncology, University of Padova, Via Giustiniani, Padova, Italy. pietro.ruggieri@unipd.it.
Abstract
PURPOSES: Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma. We analyzed (1) oncologic outcome in a large homogeneous series and (2) the role of prognostic factors on prognosis, local recurrence and metastasis. METHODS: Eighty-seven patients (47 males, 54 %) were retrospectively analyzed. All except 4 had extracompartmental disease, and ten patients had lung metastasis at diagnosis. Pathologic fracture was present in 27 cases (31 %). Seventy-eight patients were treated with neoadjuvant chemotherapy; nine had surgery as first treatment. Limb-salvage surgery was performed in 71 cases, amputation in 14, and rotationplasty in one. One patient died before surgery. Possible prognostic factors were statistically evaluated. RESULTS: Overall survival was 60.7 % at 10 years of follow-up. Fifty-one patients were disease-free (58.6 %), 2 were alive with disease (2.3 %), 31 died with disease (35.6 %), and 3 died of other causes (3.4 %). Ten local recurrences were observed (11 %). Twenty-five patients (29 %) developed lung (22) or bone (3) metastases. No statistical difference was found considering age, metastases at diagnosis, gender, pathologic fracture, tumor volume, compartmental status, number of neoadjuvant chemotherapy agents and treatment. Induced necrosis was significant at both univariate and multivariate analysis (p < 0.0001). CONCLUSIONS: TOS does not have a poor prognosis as previously reported in literature, with a survival of about 60 % at 10 years. Most of patients can be cured with neoadjuvant chemotherapy plus surgery (limb sparing surgery is possible and safe). Tumor response to chemotherapy as induced necrosis was the only significant prognostic factors on survival, even if small tumor volume at diagnosis correlates with better prognosis at univariate analysis. LEVEL OF EVIDENCE: IV.
PURPOSES: Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma. We analyzed (1) oncologic outcome in a large homogeneous series and (2) the role of prognostic factors on prognosis, local recurrence and metastasis. METHODS: Eighty-seven patients (47 males, 54 %) were retrospectively analyzed. All except 4 had extracompartmental disease, and ten patients had lung metastasis at diagnosis. Pathologic fracture was present in 27 cases (31 %). Seventy-eight patients were treated with neoadjuvant chemotherapy; nine had surgery as first treatment. Limb-salvage surgery was performed in 71 cases, amputation in 14, and rotationplasty in one. One patient died before surgery. Possible prognostic factors were statistically evaluated. RESULTS: Overall survival was 60.7 % at 10 years of follow-up. Fifty-one patients were disease-free (58.6 %), 2 were alive with disease (2.3 %), 31 died with disease (35.6 %), and 3 died of other causes (3.4 %). Ten local recurrences were observed (11 %). Twenty-five patients (29 %) developed lung (22) or bone (3) metastases. No statistical difference was found considering age, metastases at diagnosis, gender, pathologic fracture, tumor volume, compartmental status, number of neoadjuvant chemotherapy agents and treatment. Induced necrosis was significant at both univariate and multivariate analysis (p < 0.0001). CONCLUSIONS: TOS does not have a poor prognosis as previously reported in literature, with a survival of about 60 % at 10 years. Most of patients can be cured with neoadjuvant chemotherapy plus surgery (limb sparing surgery is possible and safe). Tumor response to chemotherapy as induced necrosis was the only significant prognostic factors on survival, even if small tumor volume at diagnosis correlates with better prognosis at univariate analysis. LEVEL OF EVIDENCE: IV.
Entities:
Keywords:
Bone sarcoma; Chemotherapy; Pathologic fracture; Prognostic factors; Statistical analysis
Authors: G Bacci; A Briccoli; S Ferrari; A Longhi; M Mercuri; R Capanna; D Donati; S Lari; C Forni; M DePaolis Journal: Eur J Cancer Date: 2001-11 Impact factor: 9.162
Authors: G Bacci; S Ferrari; A Longhi; P Picci; M Mercuri; T A Alvegard; G Saeter; D Donati; M Manfrini; S Lari; A Briccoli; C Forni Journal: J Chemother Date: 2002-04 Impact factor: 1.714
Authors: Sigbjørn Smeland; Stefan S Bielack; Jeremy Whelan; Mark Bernstein; Pancras Hogendoorn; Mark D Krailo; Richard Gorlick; Katherine A Janeway; Fiona C Ingleby; Jakob Anninga; Imre Antal; Carola Arndt; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Michael Capra; Catharina Dhooge; Mikael Eriksson; Adrienne M Flanagan; Godehard Friedel; Mark C Gebhardt; Hans Gelderblom; Robert Goldsby; Holcombe E Grier; Robert Grimer; Douglas S Hawkins; Stefanie Hecker-Nolting; Kirsten Sundby Hall; Michael S Isakoff; Gordana Jovic; Thomas Kühne; Leo Kager; Thekla von Kalle; Edita Kabickova; Susanna Lang; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Regine Mayer-Steinacker; Paul A Meyers; Raj Nagarajan; R Lor Randall; Peter Reichardt; Marleen Renard; Catherine Rechnitzer; Cindy L Schwartz; Sandra Strauss; Lisa Teot; Beate Timmermann; Matthew R Sydes; Neyssa Marina Journal: Eur J Cancer Date: 2019-01-25 Impact factor: 9.162